ArticleBiomedicines2023
Synergistic Benefits: Exploring the Anti-Virulence Effects of Metformin/Vildagliptin Antidiabetic Combination against
Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- Disarming Pseudomonas aeruginosa: repurposing vardenafil, valsartan, and olmesartan as anti-virulence and antibiofilm agents.Scientific reports · 2026Article
- Article
- Unveiling the Role of Pseudomonas aeruginosa Quorum Sensing Inhibitors: The Road So Far.Chemical record (New York, N.Y.) · 2026Review
- Metformin as a Metabolic Reprogramming Interface in Host-Pathogen and Bone Microenvironment Crosstalk: A Dual-Target Strategy Against Antimicrobial Resistance and Osteoporotic Bone Loss.Antibiotics (Basel, Switzerland) · 2026Review
- Metformin as an Adjunct in Periodontal Therapy: Mechanistic Insights, Research Evidence and Current Challenges.Therapeutic innovation & regulatory science · 2026Review
- Disclosing New Insights on Pyrazolo[3,4-Journal of microbiology and biotechnology · 2025Article
- Repurposing MK-8245 as a Quorum Sensing Inhibitor to Suppress Virulence and Potentiate Antibiotic Activity inAntibiotics (Basel, Switzerland) · 2025Article
- Adhesin genes expression among carbapenem-resistant uropathogenic Escherichia coli exposed to linalool and metformin.Molecular biology reports · 2025Article
- From Control to Cure: Insights into the Synergy of Glycemic and Antibiotic Management in Modulating the Severity and Outcomes of Diabetic Foot Ulcers.International journal of molecular sciences · 2025Review
- Vitamin D3 potentiates antimicrobial and antibiofilm activities of streptomycin and thymoquinone against Pseudomonas aeruginosa.World journal of microbiology & biotechnology · 2025Article
- Reprofiling lamivudine as an antibiofilm and anti-pathogenic agent against Pseudomonas aeruginosa.AMB Express · 2025Article
- Enoxacin adversely affects Salmonella enterica virulence and host pathogenesis through interference with type III secretion system type II (T3SS-II) and disruption of translocation of Salmonella Pathogenicity Island-2 (SPI2) effectors.Journal of microbiology (Seoul, Korea) · 2025Article
- Celastrol boosts fluconazole efficacy against vaginal candidiasis: in vitro and in vivo evidence.AMB Express · 2025Article
- Sulforaphane Is Not Only a Food Supplement: It Diminishes the Intracellular Survival and Colonization ofACS omega · 2025Article
- Phenazine Scaffolds as a Potential Allosteric Inhibitor of LasR Protein inBioinformatics and biology insights · 2025Article
- Quorum Sensing and its Inhibition inCurrent drug targets · 2025Review
- Arctigenin from Burdock Root Exhibits Potent Antibacterial and Anti-Virulence Properties againstJournal of microbiology and biotechnology · 2024Article
- Cilostazol is a promising anti-pseudomonal virulence drug by disruption of quorum sensing.AMB Express · 2024Article
- Quorum Sensing Inhibitors: An Alternative Strategy to Win the Battle against Multidrug-Resistant (MDR) Bacteria.Molecules (Basel, Switzerland) · 2024Review
- Miconazole and phenothiazine hinder the quorum sensing regulated virulence in Pseudomonas aeruginosa.The Journal of antibiotics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The repurposing of drugs is one of the most competent strategies for discovering new antimicrobial agents. Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPI-4) that is used effectively in combination with metformin to control blood glucose levels in diabetic patients. This study was designed to evaluate the anti-virulence activities of this combination against one of the most clinically important pathogens,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.